INCY vs LMAT: fair value comparison
Incyte Corporation and LeMaitre Vascular, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, INCY currently sits closer to the top of our discount ranking. INCY carries the stronger quality grade.
| INCY | LMAT | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $124.37 | $103.61 |
| 12-month range | $85.98–$119.52 | $79.78–$111.76 |
| Sector rank | #35 of 113 Healthcare | #37 of 113 Healthcare |
| Quality grade | A | C+ |
| Momentum grade | A | — |
| Leverage | Low | Low |
| Margin trend | Stable | — |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: INCY fair value analysis · LMAT fair value analysis